<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">



EUP-1.jpg

 

 

WINNER 

f-star_hi_large

EU Private Company of the Year 2

The Award

This award recognises a European private life science company that has demonstrated a superior excellence in strategy, process, focus and execution to create significant value for patients, investors, employees and the broader life science community.Judges paid particular attention to:

  • Use of innovative approaches to target unmet medical need.
  • Strength of management team leadership and performance.
  • Any capital raise execution and outcomes.
  • Progress through drug discovery/pre-clinical/clinical stages.
  • Key stages of strategic development/partnerships/transactions.

Company Description  

F-star is a leader in the discovery and development of novel bispecific antibodies F-star is a biopharmaceutical company focused on developing immuno-oncology bispecific antibody therapeutics.

We are poised to dominate the bispecific antibody space in immuno-oncology through the application of our highly efficient Modular Antibody Technology™ platform. Our powerful platform enables the discovery of novel bispecific antibodies, which are selected for their potential to transform the treatment of cancer.

The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including: AbbVie, Bristol-Myers Squibb, Merck KGaA and Denali Therapeutics.

We have built a comprehensive IP estate around our technology and product pipeline, with over 350 granted patents and more than 40 pending applications. F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics.

The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. F-star currently employs over 90 people at its research site in Cambridge, UK.

DOWNLOAD THE 2018 WINNERS